344 related articles for article (PubMed ID: 28755883)
1. Metformin: Insights into its anticancer potential with special reference to AMPK dependent and independent pathways.
Ikhlas S; Ahmad M
Life Sci; 2017 Sep; 185():53-62. PubMed ID: 28755883
[TBL] [Abstract][Full Text] [Related]
2. The antidiabetic drug metformin inhibits uterine leiomyoma cell proliferation via an AMP-activated protein kinase signaling pathway.
Li B; Takeda T; Tsuiji K; Kondo A; Kitamura M; Wong TF; Yaegashi N
Gynecol Endocrinol; 2013 Jan; 29(1):87-90. PubMed ID: 22835064
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma.
Zheng L; Yang W; Wu F; Wang C; Yu L; Tang L; Qiu B; Li Y; Guo L; Wu M; Feng G; Zou D; Wang H
Clin Cancer Res; 2013 Oct; 19(19):5372-80. PubMed ID: 23942093
[TBL] [Abstract][Full Text] [Related]
4. Cation-selective transporters are critical to the AMPK-mediated antiproliferative effects of metformin in human breast cancer cells.
Cai H; Zhang Y; Han TK; Everett RS; Thakker DR
Int J Cancer; 2016 May; 138(9):2281-92. PubMed ID: 26669511
[TBL] [Abstract][Full Text] [Related]
5. Metformin inhibits growth of human non-small cell lung cancer cells via liver kinase B-1-independent activation of adenosine monophosphate-activated protein kinase.
Guo Q; Liu Z; Jiang L; Liu M; Ma J; Yang C; Han L; Nan K; Liang X
Mol Med Rep; 2016 Mar; 13(3):2590-6. PubMed ID: 26847819
[TBL] [Abstract][Full Text] [Related]
6. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth.
Rocha GZ; Dias MM; Ropelle ER; Osório-Costa F; Rossato FA; Vercesi AE; Saad MJ; Carvalheira JB
Clin Cancer Res; 2011 Jun; 17(12):3993-4005. PubMed ID: 21543517
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic mechanisms underlying antidiabetic drug metformin's chemopreventive effect against colorectal cancer.
Jaromy M; Miller JD
Eur J Pharmacol; 2021 Apr; 897():173956. PubMed ID: 33617821
[TBL] [Abstract][Full Text] [Related]
8. Metabolic roles of AMPK and metformin in cancer cells.
Choi YK; Park KG
Mol Cells; 2013 Oct; 36(4):279-87. PubMed ID: 23794020
[TBL] [Abstract][Full Text] [Related]
9. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
10. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
[TBL] [Abstract][Full Text] [Related]
11. Metformin inhibits growth of eutopic stromal cells from adenomyotic endometrium via AMPK activation and subsequent inhibition of AKT phosphorylation: a possible role in the treatment of adenomyosis.
Xue J; Zhang H; Liu W; Liu M; Shi M; Wen Z; Li C
Reproduction; 2013 Oct; 146(4):397-406. PubMed ID: 23904524
[TBL] [Abstract][Full Text] [Related]
12. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
[TBL] [Abstract][Full Text] [Related]
13. Anticancer effects of metformin on neuroendocrine tumor cells in vitro.
Vlotides G; Tanyeri A; Spampatti M; Zitzmann K; Chourdakis M; Spttl C; Maurer J; Nölting S; Göke B; Auernhammer CJ
Hormones (Athens); 2014; 13(4):498-508. PubMed ID: 25402373
[TBL] [Abstract][Full Text] [Related]
14. Metformin as an Anticancer Agent.
Vancura A; Bu P; Bhagwat M; Zeng J; Vancurova I
Trends Pharmacol Sci; 2018 Oct; 39(10):867-878. PubMed ID: 30150001
[TBL] [Abstract][Full Text] [Related]
15. Molecular targets of metformin antitumor action.
Sośnicki S; Kapral M; Węglarz L
Pharmacol Rep; 2016 Oct; 68(5):918-25. PubMed ID: 27362768
[TBL] [Abstract][Full Text] [Related]
16. Metformin - its potential anti-cancer and anti-aging effects.
Podhorecka M; Ibanez B; Dmoszyńska A
Postepy Hig Med Dosw (Online); 2017 Mar; 71(0):170-175. PubMed ID: 28258677
[TBL] [Abstract][Full Text] [Related]
17. Metformin and cancer therapy.
Bost F; Sahra IB; Le Marchand-Brustel Y; Tanti JF
Curr Opin Oncol; 2012 Jan; 24(1):103-8. PubMed ID: 22123231
[TBL] [Abstract][Full Text] [Related]
18. Lessons from Nature: Sources and Strategies for Developing AMPK Activators for Cancer Chemotherapeutics.
Arkwright RT; Deshmukh R; Adapa N; Stevens R; Zonder E; Zhang Z; Farshi P; Ahmed RS; El-Banna HA; Chan TH; Dou QP
Anticancer Agents Med Chem; 2015; 15(5):657-71. PubMed ID: 25511514
[TBL] [Abstract][Full Text] [Related]
19. Anti-diabetic drug metformin: challenges and perspectives for cancer therapy.
Snima KS; Pillai P; Cherian AM; Nair SV; Lakshmanan VK
Curr Cancer Drug Targets; 2014; 14(8):727-36. PubMed ID: 25329671
[TBL] [Abstract][Full Text] [Related]
20. The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical development.
Gong J; Kelekar G; Shen J; Shen J; Kaur S; Mita M
Target Oncol; 2016 Aug; 11(4):447-67. PubMed ID: 26864078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]